To determine whether CD4+ or CD8+ cells contributed to the antitumor immunity, anti-CD4 or anti-CD8 antibodies were intraperitoneally injected into the rSur-FLIPr-immunized mice one day before tumor inoculation. Here, CD8A is linked to neoplasm.